Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 818,973
  • Shares Outstanding, K 53,809
  • Annual Sales, $ 91,370 K
  • Annual Income, $ -147,030 K
  • EBIT $ -168 M
  • EBITDA $ -160 M
  • 60-Month Beta 0.09
  • Price/Sales 8.96
  • Price/Cash Flow N/A
  • Price/Book 1.53

Options Overview Details

View History
  • Implied Volatility 109.55% ( -19.89%)
  • Historical Volatility 124.11%
  • IV Percentile 81%
  • IV Rank 28.17%
  • IV High 262.36% on 11/19/24
  • IV Low 49.62% on 06/25/24
  • Put/Call Vol Ratio 1.10
  • Today's Volume 44
  • Volume Avg (30-Day) 1,064
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 15,577
  • Open Int (30-Day) 25,371

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -1.01
  • Number of Estimates 6
  • High Estimate -0.58
  • Low Estimate -1.22
  • Prior Year -1.26
  • Growth Rate Est. (year over year) +19.84%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.70 +29.49%
on 12/18/24
17.66 -14.21%
on 12/19/24
+0.55 (+3.77%)
since 11/22/24
3-Month
11.70 +29.49%
on 12/18/24
22.25 -31.91%
on 09/24/24
-6.85 (-31.14%)
since 09/23/24
52-Week
11.70 +29.49%
on 12/18/24
41.54 -63.53%
on 01/09/24
-24.12 (-61.42%)
since 12/22/23

Most Recent Stories

More News
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study

Roche RHHBY announced data from the phase IIb PADOVA study which evaluated its investigational monoclonal antibody, prasinezumab, for treating people with early-stage Parkinson’s disease.The double-blind...

CSTL : 27.33 (-0.73%)
PRTA : 15.05 (-1.12%)
RHHBY : 34.6800 (+0.52%)
SPRO : 0.9674 (+1.29%)
Prothena: Q3 Earnings Snapshot

Prothena: Q3 Earnings Snapshot

PRTA : 15.05 (-1.12%)
Prothena: Q2 Earnings Snapshot

Prothena: Q2 Earnings Snapshot

PRTA : 15.05 (-1.12%)
Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial...

PRTA : 15.05 (-1.12%)
Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 15.05 (-1.12%)
Prothena to Participate in 2023 Bank of America Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 15.05 (-1.12%)
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety...

PRTA : 15.05 (-1.12%)
WBA : 9.31 (-2.51%)
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new...

PRTA : 15.05 (-1.12%)
Prothena to Participate in Stifel 2023 Virtual CNS Days

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 15.05 (-1.12%)
Biotech Sector Working Fast to Combat Alzheimer’s Disease Cases That are Set to Explode

FN Media Group Presents USA News Group News Commentary   Vancouver, BC – March 15, 2023 – USA News Group  –  According to a 2022 study of more than 6 million patients 65 and older, the risk factor...

MRVL.VN : 0.160 (unch)
BIIB : 148.00 (+1.04%)
PRTA : 15.05 (-1.12%)
ITCI : 83.58 (+0.16%)
RHHBY : 34.6800 (+0.52%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 17.38
2nd Resistance Point 16.90
1st Resistance Point 16.06
Last Price 15.05
1st Support Level 14.74
2nd Support Level 14.26
3rd Support Level 13.42

See More

52-Week High 41.54
Fibonacci 61.8% 30.14
Fibonacci 50% 26.62
Fibonacci 38.2% 23.10
Last Price 15.05
52-Week Low 11.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar